Shareholder Letter from Chairman of China Sky One Medical

HARBIN, China, Jan. 21, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company in the People's Republic of China ("PRC"), today announced the shareholder letter from Mr. Yanqing Liu, the Company's Chairman of Board of Directors, and Chief Executive Officer. The full text of this shareholder letter is as follows:

Dear Shareholders,

Our company's reputation continues to be tarnished by unfounded allegations of certain self-serving investors, whose viewpoints recently have been rehashed in media outlets, driving our share price down and create panic among our valued shareholders.

We regret that our faithful shareholders have suffered loss in the capital market as a result of reckless criticism and attacks. Most of the issues that recently resurfaced in the media were raised some time ago and have already been addressed by management. We have worked closely and diligently with all SEC inquiries and will continue to do so.

As you know, despite all attempts, China Sky One Medical is one of China's leading pharmaceutical companies. We manufacture and distribute over 100 products across approximately 30,000 pharmacies and 1,000 hospitals throughout China. We will continue to focus on delivering strong operating performance, which should provide a key source of confidence for our shareholders in the long run. So far, there are not many shareholders who have been visiting the Company, or met with our management team. Without conducting field research or seeing firsthand the dedication of our professionals, we consider the negative challenges have demonstrated little interest in knowing the business.

China Sky One Medical operates four pharmaceutical factories and two R&D centers in China. We are well positioned in the country's pharmaceutical industry, with strong R&D capabilities and expanding marketing and branding strategies. The Company has a world-class product pipeline, which represents huge business potential. Based on China Sky One's fundamentals, the management is optimistic for a brighter future.

In the Company's history, our executive directors have never sold a single share of China Sky One Medical. Despite all the accusations, we will keep focusing on business development and continue to focus on managing our business to create long term shareholder value. We also intend to continue to update investors regularly through press releases as we reach any key milestones in 2011, including research and development progress, as well as new business advances. We highly value smooth and transparent communication with our investors.

Management is now busy working on annual auditing and reporting for 2010. As soon as practical, we intend to update investors on our 2010 performance and our financial guidance for 2011.

To provide foreign investors a better opportunity to understand the real China Sky One Medical, especially at this critical time, we want to extend a sincere open invitation to our current shareholders, potential investors, and different opinion holders to visit our headquarters and pharmacies in China. We will show you how we manage the business from manufacturing to distributing. We are willing to cover your travel expenses in China. "Seeing is the base of believing." China Sky One Medical truly welcomes investors and media to come visiting us and understand how we conduct our business with their own eyes!

Mr. Yanqing Liu

Chairman of Board of Directors, and Chief Executive Officer

China Sky One Medical

(End of the shareholder letter)

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang Pharmaceutical Company, the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn.

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the Company's product pipeline, sales and marketing as well as other financial or operational information. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.